<h3>Objective:</h3> To conduct a systematic review with meta-analysis to summarize the current evidence on MPV as a potential biomarker for functional outcome in patients with acute ischemic stroke. <h3>Background:</h3> Evidence has shown an association between blood biomarkers, such as mean platelet volume (MPV), and the formation of thrombosis and embolisms. <h3>Design/Methods:</h3> A systematic search was conducted in PubMed, Embase, Scopus, Web of Science, and Google Scholar until December 2021. A meta-analysis was applied with a random effects model by the Paule-Mandel estimator. Likewise, a subgroup analysis was performed according to the treatment reveived by patients. Sensitivity analysis was performed using exclusion meta-analysis and the Dersimonian-Laird estimator. To identify the certainty of the evidence, the GRADE criteria for continuous outcomes were performed. <h3>Results:</h3> We selected 37 studies from our initial search. A meta-analysis of 9 studies (1707 patients) with moderate certainty of the evidence showed that higher MPV levels at hospital admission were predictor of poor functional outcome (modified Rankin Scale >2) at three months (Difference of means [DM]: 0.64; 95% CI: 0.33, 0.94; I2= 78%). An analysis by subgroups was performed according to the treatment administered and no statistically significant differences were found (Intravenous thrombolysis [DM]: 0.82; 95% CI: 0.22, 1.42; I2= 82%; Treatment not specified [DM]: 0.49; 95% CI: 0.20, 0.78; I2= 75%). Likewise, the sensitivity analysis did not weaken our results. <h3>Conclusions:</h3> With moderate certainty of the evidence, we found that MPV is useful as a prognostic biomarker in patients with acute ischemic stroke. These results can help to identify patients with greater severity; however, more research is required to control posible confounding variables through sensitivity and specificity analysis. <b>Disclosure:</b> Miss Pascual-Guevara has nothing to disclose. Mr. Cabanillas Lazo has nothing to disclose. Miss Cruzalegui Bazán has nothing to disclose. Mr. Vicuña has nothing to disclose. Miss Cierto Torre has nothing to disclose. Mr. Vallejos has nothing to disclose. Dr. Sequeiros Chirinos has nothing to disclose. Carlos Alva-Diaz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Farma. Carlos Alva-Diaz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Farma. The institution of Carlos Alva-Diaz has received research support from Roche farma.